Q-omics provides the consensus-scored TXNP5 profile across patient tissues and cancer cell-line models. TXNP5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TXNP5 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, TXNP5 RNA expression shows 11,772 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, COAD, and LSCC as cancer lineages where TXNP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNP5 survival associations across molecular data types. TXNP5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNP5 RNA expression–survival associations across cancer types. High TXNP5 expression shows unfavorable associations in LIHC, PAAD, SKCM and UCS, but favorable associations in CESC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TXNP5 RNA expression.
This table summarizes TXNP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TXNP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNP5 shows higher tumor expression in COAD, UCEC, LUSC, BRCA, LIHC and LUAD. The COAD box plot shows higher TXNP5 RNA expression in tumor versus normal tissue (log2 FC = +1.486, t-test p < 0.001).
This table shows molecular features associated with TXNP5 in patient tissues and cancer cell lines. In patient samples, TXNP5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
